前列腺是临床上重要的男性附属生殖腺，对精液产生至关重要。前列腺癌现时在香港男性癌症年度发病率中排名第3位，在男性癌症相关死亡中排名第5位，每100,000人约有10.9宗死亡。其发病率正迅速上升，过去10年几乎增加三倍。
适应症：Prostate Cancer
入组条件
纳入标准
- For non prostate cancer group
- Male subject with age 45 or above
- No clinical evidence of PCa, serum PSA \<4 ng/dl and normal digital rectal examination.
- For prostate cancer group
- Male subject with age 45 or above
- Clinically diagnosed to have localized PCa and planned for radical prostatectomy
- No prior systemic therapy for PCa used, including hormonal or chemotherapy.
排除标准
- History of medications usage that can affect serum PSA levels within 6 months of study enrolment.
- History of active urinary tract infection within 1 month of study enrolment.
- History of invasive prostate / bladder treatments within 6 months of study enrolment.
- History of concurrent renal/bladder cancer within 6 months of study enrolment.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年11月5日。